Request Demo
Recent blog posts
Latest Hotspot
8 min read
Renal medullary carcinoma Indication Strategy Report 2026: INI1, Trials and Deals
21 July 2026
Renal medullary carcinoma indication strategy report covering epidemiology, INI1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Chromophobe renal cell carcinoma Indication Strategy Report 2026: FLCN, Trials and Deals
21 July 2026
Chromophobe renal cell carcinoma indication strategy report covering epidemiology, FLCN biology, active trials, competition and deal signals using PatSnap MCP...
Latest Hotspot
8 min read
Papillary renal cell carcinoma Indication Strategy Report 2026: c-Met, Trials and Deals
21 July 2026
Papillary renal cell carcinoma indication strategy report covering epidemiology, c-Met biology, active trials, competition and deal signals using PatSnap MCP...
Latest Hotspot
8 min read
Paraganglioma Indication Strategy Report 2026: SDHB, Trials and Deals
21 July 2026
Paraganglioma indication strategy report covering epidemiology, SDHB biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Pheochromocytoma Indication Strategy Report 2026: HIF-2α, Trials and Deals
21 July 2026
Pheochromocytoma indication strategy report covering epidemiology, HIF-2α biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Adrenocortical carcinoma Indication Strategy Report 2026: IGF-1R, Trials and Deals
21 July 2026
Adrenocortical carcinoma indication strategy report covering epidemiology, IGF-1R biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Medullary thyroid carcinoma Indication Strategy Report 2026: RET, Trials and Deals
21 July 2026
Medullary thyroid carcinoma indication strategy report covering epidemiology, RET biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
NCT07667803 Elecoglipron Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07667803 clinical trial report covering Elecoglipron, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600127139 L-Isoleucine/L-Leucine/L-Valine Unresectable Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
ChiCTR2600127139 clinical trial report covering L-Isoleucine/L-Leucine/L-Valine, Phase 2, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
NCT07668141 Lipoic acid Nephrotoxicity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07668141 clinical trial report covering Lipoic acid, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07669415 Tislelizumab Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07669415 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07669740 Albumin-Bound Paclitaxel Stomach Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07669740 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.